Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced on 30 April that the first patient has been dosed in a confirmatory Phase 2b clinical trial designed to further evaluate the safety, tolerability and efficacy of certain doses of FX006 as a treatment for relieving pain associated with OA of the knee. Flexion Therapeutics Inc. (NASDAQ:FLXN) shares after opening at $11.79 moved to $11.87 on last trade day and at the end of the day closed at $11.86. Company price to sales ratio in past twelve months was calculated as – and price to cash ratio as 8.82. Flexion Therapeutics Inc. (NASDAQ:FLXN) showed a negative weekly performance of -11.36%.
TearLab Corporation (NASDAQ:TEAR) expects to announce its Q1 2014 financial results after market closes on Thursday May 8, 2014. TearLab Corp (NASDAQ:TEAR) shares fell -2.08% in last trading session and ended the day on $4.23. TEAR return on equity ratio is recorded as -156.80% and its return on assets is -104.40%. TearLab Corp (NASDAQ:TEAR) yearly performance is -43.97%.
Tesaro Inc. (NASDAQ:TSRO) a Waltham-based oncology-focused biopharmaceutical company, announces its first quarter 2014 financial results on April 30 after the close of the U.S. financial markets. TESARO Inc. (NASDAQ:TSRO) shares moved down -3.77% in last trading session and was closed at $24.02, while trading in range of $22.75 – $24.99. TESARO Inc. (NASDAQ:TSRO) year to date (YTD) performance is -14.94%.
Having raised a net $15.4 million after its initial public offering and related expenses, Santa Rosa-based Ruthigen (NASDAQ:RTGN) will now be able to fully fund the first two phases of clinical trials for a preventative antibiotic treatment designed for use in surgery and wound care, said chief executive Hojabr “Hoji” Alimi. Ruthigen Inc. (NASDAQ:RTGN) weekly performance is -3.16%. On last trading day company shares ended up $6.74. Ruthigen Inc. (NASDAQ:RTGN) distance from 50-day simple moving average (SMA50) is -2.97%.
Leave a Reply